243 related articles for article (PubMed ID: 10417495)
61. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects.
Dingemanse J; Wood N; Guentert T; Oie S; Ouwerkerk M; Amrein R
Psychopharmacology (Berl); 1998 Nov; 140(2):164-72. PubMed ID: 9860107
[TBL] [Abstract][Full Text] [Related]
62. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine.
Gijsman H; Kramer MS; Sargent J; Tuchman M; Matzura-Wolfe D; Polis A; Teall J; Block G; Ferrari MD
Cephalalgia; 1997 Oct; 17(6):647-51. PubMed ID: 9350384
[TBL] [Abstract][Full Text] [Related]
63. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan.
Dixon R; French S; Kemp J; Sellers M; Leclerc V; Delvaux M; Rautureau J
J Clin Pharmacol; 1998 Aug; 38(8):694-701. PubMed ID: 9725544
[TBL] [Abstract][Full Text] [Related]
64. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study.
Visser WH; Klein KB; Cox RC; Jones D; Ferrari MD
Neurology; 1996 Feb; 46(2):522-6. PubMed ID: 8614525
[TBL] [Abstract][Full Text] [Related]
65. Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine.
Pascual J; Bussone G; Hernandez JF; Allen C; Vrijens F; Patel K;
Eur Neurol; 2001; 45(4):275-83. PubMed ID: 11385269
[TBL] [Abstract][Full Text] [Related]
66. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers.
Berlin I; Saïd S; Spreux-Varoquaux O; Launay JM; Olivares R; Millet V; Lecrubier Y; Puech AJ
Clin Pharmacol Ther; 1995 Oct; 58(4):444-52. PubMed ID: 7586937
[TBL] [Abstract][Full Text] [Related]
67. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.
Seeburger JL; Taylor FR; Friedman D; Newman L; Ge Y; Zhang Y; Hustad CM; Lasorda J; Fan X; Hewitt D; Ho T; Connor KM
Cephalalgia; 2011 May; 31(7):786-96. PubMed ID: 21078681
[TBL] [Abstract][Full Text] [Related]
68. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
Berges A; Walls C; Lener SE; McDonald SA
Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
[TBL] [Abstract][Full Text] [Related]
69. A review of the 5-HT1B/1D agonist rizatriptan: update on recent research and implications for the future.
Mannix LK
Expert Opin Pharmacother; 2008 Apr; 9(6):1001-11. PubMed ID: 18377342
[TBL] [Abstract][Full Text] [Related]
70. The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects.
Tfelt-Hansen P; Seidelin K; Stepanavage M; Lines C
Br J Clin Pharmacol; 2002 Jul; 54(1):38-44. PubMed ID: 12100223
[TBL] [Abstract][Full Text] [Related]
71. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
Seaber E; On N; Dixon RM; Gibbens M; Leavens WJ; Liptrot J; Chittick G; Posner J; Rolan PE; Pack RW
Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
[TBL] [Abstract][Full Text] [Related]
72. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers.
Seaber E; On N; Phillips S; Churchus R; Posner J; Rolan P
Br J Clin Pharmacol; 1996 Feb; 41(2):141-7. PubMed ID: 8838441
[TBL] [Abstract][Full Text] [Related]
73. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
Christie S; Göbel H; Mateos V; Allen C; Vrijens F; Shivaprakash M;
Eur Neurol; 2003; 49(1):20-9. PubMed ID: 12464714
[TBL] [Abstract][Full Text] [Related]
74. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine.
Bomhof M; Paz J; Legg N; Allen C; Vandormael K; Patel K
Eur Neurol; 1999; 42(3):173-9. PubMed ID: 10529545
[TBL] [Abstract][Full Text] [Related]
75. Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect.
Fox AW
Headache; 2010 Feb; 50(2):249-55. PubMed ID: 19925626
[TBL] [Abstract][Full Text] [Related]
76. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine.
McEnroe JD; Fleishaker JC
Clin Pharmacokinet; 2005; 44(3):237-46. PubMed ID: 15762767
[TBL] [Abstract][Full Text] [Related]
77. Effects of 5-HT1B/1D receptor agonist rizatriptan on cerebral blood flow and blood volume in normal circulation.
Okazawa H; Tsuchida T; Pagani M; Mori T; Kobayashi M; Tanaka F; Yonekura Y
J Cereb Blood Flow Metab; 2006 Jan; 26(1):92-8. PubMed ID: 15944648
[TBL] [Abstract][Full Text] [Related]
78. Patient satisfaction with rizatriptan versus other triptans: direct head-to-head comparisons.
Gerth WC; McCarroll KA; Santanello NC; Vandormael K; Zhang Q; Mannix LK
Int J Clin Pract; 2001 Oct; 55(8):552-6. PubMed ID: 11695077
[TBL] [Abstract][Full Text] [Related]
79. Non-invasive assessment of selective 5-HT(1B/1D)-receptor agonist-induced peripheral vascular effects in humans: comparison of different techniques.
Vanmolkot FH; de Hoon JN; Barrington P; Peck RW; Dallow NS; Williams PM; McColm J
Eur J Clin Pharmacol; 2002 Aug; 58(5):303-8. PubMed ID: 12185552
[TBL] [Abstract][Full Text] [Related]
80. Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of alpha 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers.
Scheinin M; Karhuvaara S; Ojala-Karlsson P; Kallio A; Koulu M
Life Sci; 1991; 49(1):75-84. PubMed ID: 1646924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
